An open-label Phase I study to assess the safety of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients
Brief description of study
If you have been diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), you may qualify for this Phase I study. The main goal of this study is to test the safety of a Chimeric Antigen Receptor Therapy (CAR-T) known as NKR-2 and understand how well NKR-2 works to destroy cancer cells in your body.
Clinical Study Identifier: s18-00159
ClinicalTrials.gov Identifier: NCT03466320
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
